Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney Dawson

Showing results (31-40 of 94) with videos related to

Pageof 10
Sort By:
The Lancet. Microbe|April 9, 2021
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trialAndreas Diacon, Sachiko Miyahara, Rodney Dawson, et al.
American Journal of Respiratory and Critical Care Medicine|March 21, 2025
Telacebec, A Potent Agent in the Fight Against Tuberculosis: Findings from A Randomized, Phase 2 Clinical Trial and BeyondSaskia Janssen, Caryn Upton, Veronique R de Jager, et al.
The New England Journal of Medicine|March 27, 2020
Telacebec (Q203), a New Antituberculosis AgentVeronique R de Jager, Rodney Dawson, Christo van Niekerk, et al.
Plos One|October 2, 2014
Adenosine deaminase acting on RNA-1 (ADAR1) inhibits HIV-1 replication in human alveolar macrophagesMichael D Weiden, Satomi Hoshino, David N Levy, et al.
Frontiers in Pharmacology|March 31, 2023
Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug developmentRami Ayoun Alsoud, Robin J Svensson, Elin M Svensson, et al.
Plos One|January 26, 2013
Development of a simple reliable radiographic scoring system to aid the diagnosis of pulmonary tuberculosisLancelot M Pinto, Keertan Dheda, Grant Theron, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 3, 2024
Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis PreventionAnthony T Podany, Yoninah Cramer, Marjorie Imperial, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2012
Phase II dose-ranging trial of the early bactericidal activity of PA-824Andreas H Diacon, Rodney Dawson, Jeannine du Bois, et al.
American Journal of Respiratory and Critical Care Medicine|April 16, 2011
Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence settingGrant Theron, Jonny Peter, Richard van Zyl-Smit, et al.
Plos One|April 16, 2014
Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosisRobert S Wallis, Rodney Dawson, Sven O Friedrich, et al.
Pageof 10

Showing results (31-40 of 94) with videos related to

Sort By:
Pageof 10
The Lancet. Microbe|April 9, 2021
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trialAndreas Diacon, Sachiko Miyahara, Rodney Dawson, et al.
American Journal of Respiratory and Critical Care Medicine|March 21, 2025
Telacebec, A Potent Agent in the Fight Against Tuberculosis: Findings from A Randomized, Phase 2 Clinical Trial and BeyondSaskia Janssen, Caryn Upton, Veronique R de Jager, et al.
The New England Journal of Medicine|March 27, 2020
Telacebec (Q203), a New Antituberculosis AgentVeronique R de Jager, Rodney Dawson, Christo van Niekerk, et al.
Plos One|October 2, 2014
Adenosine deaminase acting on RNA-1 (ADAR1) inhibits HIV-1 replication in human alveolar macrophagesMichael D Weiden, Satomi Hoshino, David N Levy, et al.
Frontiers in Pharmacology|March 31, 2023
Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug developmentRami Ayoun Alsoud, Robin J Svensson, Elin M Svensson, et al.
Plos One|January 26, 2013
Development of a simple reliable radiographic scoring system to aid the diagnosis of pulmonary tuberculosisLancelot M Pinto, Keertan Dheda, Grant Theron, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 3, 2024
Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis PreventionAnthony T Podany, Yoninah Cramer, Marjorie Imperial, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2012
Phase II dose-ranging trial of the early bactericidal activity of PA-824Andreas H Diacon, Rodney Dawson, Jeannine du Bois, et al.
American Journal of Respiratory and Critical Care Medicine|April 16, 2011
Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence settingGrant Theron, Jonny Peter, Richard van Zyl-Smit, et al.
Plos One|April 16, 2014
Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosisRobert S Wallis, Rodney Dawson, Sven O Friedrich, et al.
Pageof 10